Results
COPD
ISCHEMIC HEART DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, MAY, COPD, IHD, HEART, TYPE 2 DIABETES
Between May 2019 and October 2021, 90 patients were randomized. CA125 was available in 87 patients (96.7%) at baseline. The mean age of this study sample was 67.0 ± 10.5 years, 27 (36.0%) had type 2 diabetes, 48 (55.2%) showed prior ischemic heart disease, and 72 (82.8%) were on stable NYHA II. At baseline, the medians (p25%-p75%) of CA125 and NT-proBNP were 11 U/ml (7–17) and 1274 pg/ml (895–2267), respectively. The proportion of patients treated with sacubitril/valsartan, β-blockers, and mineralocorticoid receptor antagonists was 88.5%, 87.4%, and 74.7%, respectively. No significant differences in baseline characteristics across treatment arms were observed. (Table Baseline characteristics of the patients stratified by randomization arm.Values are expressed by mean ± standard deviation. Categorical variables are presented as percentages.Continuous variables are presented as median (interquartile range), and categorical variables are as percentages.ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CA125, Antigen Carbohydrate 125; COPD, chronic obstructive pulmonary disease; CPET, cardiopulmonary exercise testing; eGFR, estimated glomerular filtration rate; IHD, ischemic heart disease; LVEF: left ventricular ejection fraction assessed by Simpson method; MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association functional class; NT-proBNP, the natural logarithm of N-terminal prohormone of brain natriuretic peptide: PeakVO